BMS to divest Celgene drug to speed delayed deal

Bristol-Myers Squibb said it is planning to sell Otezla, Celgene ' s treatment for certain types of psoriasis and psoriatic arthritis, in an effort to address Federal Trade Commission concerns about its pending merger with Celgene.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news